Cellebrite DI (NASDAQ:CLBT) Issues Quarterly Earnings Results, Meets Expectations

Cellebrite DI (NASDAQ:CLBT) released its earnings results on Wednesday. The company reported $0.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.14, Briefing.com reports. The company had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The firm’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.10 EPS.

Here are the key takeaways from Cellebrite DI’s conference call:

• Strong 2025 financials — ARR grew 21% to $481M (17% ex‑Corellium), full‑year revenue +19%, Adjusted EBITDA expanded and free cash flow totaled $160M (34% margin).
• SaaS and cloud momentum — SaaS/cloud ARR grew >50% and now represents 22% of total ARR; Guardian sustained 100%+ YoY growth for its sixth straight quarter, boosting recurring, higher‑margin revenue.
• M&A to broaden TAM — Closed Corellium (Dec 1) and agreed to buy SCG Canada (drone forensics) to add ARM virtualization and drone capabilities; management expects long‑term accretion but Corellium adds near‑term costs and regulatory/clearance work remains.
• 2026 guidance and tighter outlook — Management set narrower targets calling for 18–19% ARR growth (to $567–573M), revenue +19–20% and Adjusted EBITDA margin ~26–27%, while targeting FCF margins >30%.
• Federal market catalysts — Company expects the U.S. federal unit to reaccelerate on pent‑up demand, increased funding and an anticipated FedRAMP Level 4 ATO that will enable Guardian/cloud adoption in federal accounts.

Cellebrite DI Price Performance

Shares of CLBT traded down $0.73 during mid-day trading on Thursday, reaching $13.53. 1,709,605 shares of the company’s stock were exchanged, compared to its average volume of 1,740,261. The business’s fifty day simple moving average is $17.21 and its 200-day simple moving average is $17.00. The stock has a market capitalization of $3.24 billion, a PE ratio of 43.64, a price-to-earnings-growth ratio of 2.08 and a beta of 1.28. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $25.03.

Institutional Trading of Cellebrite DI

Large investors have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Cellebrite DI by 16.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after purchasing an additional 24,881 shares during the period. Geode Capital Management LLC increased its position in Cellebrite DI by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after acquiring an additional 43,898 shares during the period. Invesco Ltd. raised its stake in Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after acquiring an additional 209,473 shares during the last quarter. First Trust Advisors LP acquired a new stake in Cellebrite DI during the 2nd quarter worth approximately $341,000. Finally, Marshall Wace LLP purchased a new position in shares of Cellebrite DI in the 2nd quarter valued at approximately $4,472,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI News Summary

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Reported strong Q4 results — revenue $128.8M (+28.8% YoY), total ARR up 21% to $480.8M, healthy adjusted EBITDA margin (~29.8%), and positive net income metrics, reinforcing fundamentals. PR Newswire: Q4 & FY2025 Results
• Positive Sentiment: Raised FY‑2026 revenue guidance of $565M‑$571M (above consensus ~$556M), and Q1 revenue guidance roughly in line with Street expectations — the top‑line outlook supports continued growth expectations. Press Release / Slide Deck
• Positive Sentiment: Needham left a Buy rating and ($18) target — even after the cut this implies material upside from current levels, which may limit downside and attract value/higher‑conviction buyers. Benzinga: Needham Price Target Note
• Neutral Sentiment: EPS matched expectations at $0.14 (no earnings surprise), and revenue slightly above consensus — confirms execution but lacks an upside shock. Zacks: Q4 Results
• Neutral Sentiment: Earnings call transcripts and highlights are available (Seeking Alpha, Yahoo) for investors wanting management detail on bookings, ARR cadence and margin drivers. Seeking Alpha: Call Transcript Yahoo Finance: Call Highlights
• Negative Sentiment: Needham trimmed its price target from $24 to $18 — the cut signals reduced near‑term upside expectations and may lower analyst support despite the maintained Buy. Benzinga: Needham Price Target Note
• Negative Sentiment: Technicals and positioning are weak: CLBT is trading below its 50‑ and 200‑day moving averages and near its 12‑month low, which can amplify downside pressure as momentum traders stay on the sidelines. (See market performance data.)

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CLBT shares. Bank of America lifted their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Finally, Lake Street Capital increased their target price on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.